DOCSLIB.ORG

The Proteome of Prostate Cancer Bone Metastasis Reveals

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Proteome of Prostate Cancer Bone Metastasis Reveals Published OnlineFirst July 24, 2018; DOI: 10.1158/1078-0432.CCR-18-1229 Biology of Human Tumors Clinical Cancer Research The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications Diego Iglesias-Gato1,2, Elin Thysell3, Stefka Tyanova4, Sead Crnalic5, Alberto Santos6, Thiago S. Lima1,2, Tamar Geiger7,Jurgen€ Cox4, Anders Widmark8, Anders Bergh3, Matthias Mann4,6, Amilcar Flores-Morales1,2, and Pernilla Wikstrom€ 3 Abstract Purpose: Bone is the most predominant site of distant fatty acid b-oxidation; and reduced levels of proteins were metastasis in prostate cancer, and patients have limited ther- related to cell adhesion and carbohydrate metabolism. Within apeutic options at this stage. bone metastases, we identified two phenotypic subgroups: Experimental Design: We performed a system-wide BM1, expressing higher levels of AR canonical targets, and quantitative proteomic analysis of bone metastatic prostate mitochondrial and Golgi apparatus resident proteins; and tumors from 22 patients operated to relieve spinal cord BM2, with increased expression of proliferation and DNA compression. At the time of surgery, most patients had repair–related proteins. The two subgroups, validated by the relapsed after androgen-deprivation therapy, while 5 were inverse correlation between MCM3 and prostate specific anti- previously untreated. An extended cohort of prostate cancer gen immunoreactivity, were related to disease prognosis, bone metastases (n ¼ 65) was used for immunohistochem- suggesting that this molecular heterogeneity should be con- ical validation. sidered when developing personalized therapies. Results: On average, 5,067 proteins were identified Conclusions: This work is the first system-wide quantitative and quantified per tumor. Compared with primary tumors characterization of the proteome of prostate cancer bone (n ¼ 26), bone metastases were more heterogeneous and metastases and a valuable resource for understanding the showed increased levels of proteins involved in cell-cycle etiology of prostate cancer progression. Clin Cancer Res; 1–12. progression, DNA damage response, RNA processing, and Ó2018 AACR. Introduction patients with castration-resistant bone metastases (mCRPC), their prognosis remains poor with a median survival below 2 years (4). Mortality in prostate cancer is strongly associated with devel- This is in contrast to patients harboring prostate confined tumors, opment of bone metastatic disease (1, 2). Prostate cancer metas- who have a 10-year cancer-specific survival rate above 90%, even tases are generally treated with androgen ablation (3). This for patients managed by observation protocols (5, 6). Why therapy is initially effective, but most patients relapse to a cas- metastatic tumors have a more aggressive behavior than localized tration-resistant stage. Despite recent treatment developments for tumors is not fully understood. Recent genetic studies have identified only a modest increase in the number and frequency 1 of genetic aberrations in lethal, therapy-resistant metastatic cancer Department of Drug Design and Pharmacology, Faculty of Health and Medical TP53, PTEN, FOXA1 Sciences, University of Copenhagen, Copenhagen, Denmark. 2The Danish Can- as compared with localized tumors (e.g., , and PI3KCA AR fi cer Society, Copenhagen, Denmark. 3Department of Medical Biosciences, ) with the exception of androgen receptor ( ) ampli ca- Pathology, Umea University, Umea , Sweden. 4Department of Proteomics and tions, rearrangements, and mutations, seen almost exclusively in Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany. CRPC (7, 8). One possible explanation for these findings is that 5Department of Surgical and Perioperative Sciences, Orthopaedics, Umea many of the low-frequency mutations occurring in individual 6 University, Umea, Sweden. The Novo Nordisk Foundation Centre for Protein tumors may confer growth advantages through the regulation of a Research, Faculty of Health Sciences, University of Copenhagen, Copenhagen, 7 set of core signaling pathways required for metastatic growth. For Denmark. Department of Human Molecular Genetics and Biochemistry, Sackler FOXA1 MLL2 School of Medicine, Tel Aviv University, Tel Aviv, Israel. 8Department of Radi- example, mutations in genes such as or , with fl ation Sciences, Oncology, Umea University, Umea, Sweden. apparently unrelated functions, may in uence tumor growth through a common signaling mechanism: the regulation of AR Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/). activity (9). Many of the alterations in protein signaling associated with metastatic progression have remained undiscovered, as only A. Flores-Morales and P. Wikstrom€ share senior authorship of this article. few studies have actually examined prostate bone metastases in Corresponding Author: Diego Iglesias-Gato, University of Copenhagen, Uni- depth at the proteome level (10). versitetsparken 2, Copenhagen 2100, Denmark. Phone: 4535330640; Fax: Transcriptomics or genetic analysis provides a partial view 4535325001; E-mail: [email protected] of the signaling pathways driving tumor growth because of their doi: 10.1158/1078-0432.CCR-18-1229 limited capacity to predict concentration changes at the protein Ó2018 American Association for Cancer Research. level or inform about status of protein-driven mechanisms www.aacrjournals.org OF1 Downloaded from clincancerres.aacrjournals.org on September 29, 2021. © 2018 American Association for Cancer Research. Published OnlineFirst July 24, 2018; DOI: 10.1158/1078-0432.CCR-18-1229 Iglesias-Gato et al. 24, 2007, Dnr 2013-372-32M) and conducted following the Translational Relevance principles of the Declaration of Helsinki. All participants gave We performed a global quantification of the proteins written or verbal consent. Due to the acute situation, when expressed in prostate cancer bone metastatic tumors and bone metastasis surgery is performed in order to relieve spine found wide variation in their proliferative and metabolic symptoms and paresis, logistics do not always allow written features. This variability is related to disease prognosis and consent and the local ethic review board therefore specifically should be accounted for when stratifying patients into differ- approved verbal consent as well. Verbal consent is documented ent treatments. by the physician in the patient journal. Proteomic analysis The effects of formic acid-based decalcification in the proteomic (11, 12). Quantitative proteomic analysis of tumor samples may analysis were evaluated in a separate set of samples. No obvious have a large potential to unveil novel signaling mechanisms of quantitative or qualitative protein alterations were observed clinical relevance. We have recently analyzed the proteome of (Supplementary Fig. S1A). Protein extracts were obtained from primary prostate tumors and demonstrated the upregulation of approximately 20 microtome sections of 10-mm thick 25- to 50- various proteins involved in metabolic processes in malignant mm2 tumor-enriched areas. Mass spectrometry–based proteomic compared with nonmalignant tissue (13). Remarkably, we did analysis of the bone metastasis samples was performed as previ- not observe a general increase of proteins involved in cell-cycle ously described using SuperSILAC spike-in standards for accurate progression or DNA synthesis, perhaps reflecting the low prolif- quantification (ref. 13; and extended Materials and Methods). The erative capacity of most localized prostate tumors. proteomic pipeline is summarized in Supplementary Fig. S1B. The objective of this first-in-class study was to characterize Raw data files were uploaded to ProteomeXchange. Accession prostate cancer bone metastases in depth at the protein level and, references for published primary tumors and nonmalignant adja- by integrating these results with the previously described prote- cent tissue are PXD004159, PXD004132, PXD003636, PXD003615, omic profiles of localized prostate tumors (13), to describe the PXD003515, PXD003452, and PXD003430 (13). Accession refer- proteome evolution during prostate cancer progression. Further- ence for metastatic samples is PXD009868. more, we aimed to identify putative targets for novel therapies of metastatic CRPC and also to explore whether subgroups of Bioinformatic tools and statistics prostate cancer bone metastasis exist that could potentially guide Unsupervised hierarchical clustering of metastasis samples was therapy decisions. We used system-wide quantitative mass spec- performed based on Pearson correlation coefficients as distance – trometry based proteomic analysis to describe the proteome of metrics (Fig. 1E). Gene ontology (GO) classification and enrich- prostate cancer bone metastases, and we found a high degree of ment analysis was performed using DAVID (14), and results were heterogeneity among the analyzed samples with at least two graphically represented with Cytoscape (ref. 15; Figs. 2 and 3). phenotypically distinct subgroups of bone metastases. We pro- Metastatic subgroups were defined by the Pearson correla- pose that these subgroups should be accounted for when design- tion coefficients of the SILAC ratios of each protein across the ing novel therapeutic alternatives. cohort with the average SILAC ratio of the minichromosome maintenance complex components (MCM2-7) of each indi- Materials and Methods vidual tumor (Fig. 3A). Only proteins showing 2 of
Load more

Recommended publications
  • When Cancer Spreads to the Bone
    When Cancer Spreads to the Bone John U. (pictured) was diagnosed with kidney cancer which metastasized to the bone over 10 years ago. Since then, he has had over a dozen procedures to stabilize his bones. Cancer occurs when cells in your body their cancer has spread to their bones. start growing and dividing faster than is booklet explains: normal. At rst, these cells may form into • Why bone metastases occur small clumps or tumors. But they can • How they are treated also spread to other parts of the body. When cancer spreads, it is said to have • What patients with bone metastases can “metastasized.” do to prevent broken bones and fractures It is possible for many types of cancer to spread to the bones. People with cancer can live for years after they have been told What is Bone? BONE ANATOMY Many people don’t spend much time thinking about their bones. But there’s a lot going on Trabecular Bone inside them. Bone is living, growing tissue, Blood vessels in bone marrow made up of proteins and minerals. Your bones have two layers. The outer layer— called cortical bone— is very thick. The inner layer—the trabecular (truh-BEH-kyoo-ler) bone—is very spongy. Inside the spongy bone is your bone marrow. It contains stem cells that can develop into white blood cells, red blood cells, and platelets. Cortical Bone The cells that make up the bones are always changing. There are three types of cells that are found only in bone: Osteoclasts (OS-tee-oh-klast), which break down the bone LLC, US Govt.
    [Show full text]
  • Supplemental Material Table of Contents
    Supplemental material Table of Contents Detailed Materials and Methods ......................................................................................................... 2 Perioperative period ........................................................................................................................... 2 Ethical aspects ................................................................................................................................... 4 Evaluation of heart failure ................................................................................................................. 4 Sample preparation for ANP mRNA expression .................................................................................. 5 Sample preparation for validative qRT-PCR (Postn, Myh7, Gpx3, Tgm2) ............................................ 6 Tissue fibrosis .................................................................................................................................... 7 Ventricular remodeling and histological tissue preservation ................................................................ 8 Evaluation of the histological preservation of cardiac tissue ................................................................ 9 Sample preparation and quantitative label-free proteomics analyses .................................................. 10 Statistical methods ........................................................................................................................... 12 References ........................................................................................................................................
    [Show full text]
  • Influencers on Thyroid Cancer Onset: Molecular Genetic Basis
    G C A T T A C G G C A T genes Review Influencers on Thyroid Cancer Onset: Molecular Genetic Basis Berta Luzón-Toro 1,2, Raquel María Fernández 1,2, Leticia Villalba-Benito 1,2, Ana Torroglosa 1,2, Guillermo Antiñolo 1,2 and Salud Borrego 1,2,* 1 Department of Maternofetal Medicine, Genetics and Reproduction, Institute of Biomedicine of Seville (IBIS), University Hospital Virgen del Rocío/CSIC/University of Seville, 41013 Seville, Spain; [email protected] (B.L.-T.); [email protected] (R.M.F.); [email protected] (L.V.-B.); [email protected] (A.T.); [email protected] (G.A.) 2 Centre for Biomedical Network Research on Rare Diseases (CIBERER), 41013 Seville, Spain * Correspondence: [email protected]; Tel.: +34-955-012641 Received: 3 September 2019; Accepted: 6 November 2019; Published: 8 November 2019 Abstract: Thyroid cancer, a cancerous tumor or growth located within the thyroid gland, is the most common endocrine cancer. It is one of the few cancers whereby incidence rates have increased in recent years. It occurs in all age groups, from children through to seniors. Most studies are focused on dissecting its genetic basis, since our current knowledge of the genetic background of the different forms of thyroid cancer is far from complete, which poses a challenge for diagnosis and prognosis of the disease. In this review, we describe prevailing advances and update our understanding of the molecular genetics of thyroid cancer, focusing on the main genes related with the pathology, including the different noncoding RNAs associated with the disease.
    [Show full text]
  • Premature Termination Codons in PRPF31 Cause Retinitis Pigmentosa Via Haploinsufficiency Due to Nonsense-Mediated Mrna Decay
    Premature termination codons in PRPF31 cause retinitis pigmentosa via haploinsufficiency due to nonsense-mediated mRNA decay Thomas Rio Frio, … , Jacques S. Beckmann, Carlo Rivolta J Clin Invest. 2008;118(4):1519-1531. https://doi.org/10.1172/JCI34211. Research Article Genetics Dominant mutations in the gene encoding the mRNA splicing factor PRPF31 cause retinitis pigmentosa, a hereditary form of retinal degeneration. Most of these mutations are characterized by DNA changes that lead to premature termination codons. We investigated 6 different PRPF31 mutations, represented by single-base substitutions or microdeletions, in cell lines derived from 9 patients with dominant retinitis pigmentosa. Five of these mutations lead to premature termination codons, and 1 leads to the skipping of exon 2. Allele-specific measurement of PRPF31 transcripts revealed a strong reduction in the expression of mutant alleles. As a consequence, total PRPF31 protein abundance was decreased, and no truncated proteins were detected. Subnuclear localization of the full-length PRPF31 that was present remained unaffected. Blocking nonsense-mediated mRNA decay significantly restored the amount of mutant PRPF31 mRNA but did not restore the synthesis of mutant proteins, even in conjunction with inhibitors of protein degradation pathways. Our results indicate that most PRPF31 mutations ultimately result in null alleles through the activation of surveillance mechanisms that inactivate mutant mRNA and, possibly, proteins. Furthermore, these data provide compelling evidence that the pathogenic effect of PRPF31 mutations is likely due to haploinsufficiency rather than to gain of function. Find the latest version: https://jci.me/34211/pdf Research article Premature termination codons in PRPF31 cause retinitis pigmentosa via haploinsufficiency due to nonsense-mediated mRNA decay Thomas Rio Frio,1 Nicholas M.
    [Show full text]
  • Atacicept (TACI-Ig) Inhibits Growth of TACI High Primary Myeloma Cells in SCID-Hu Mice and in Coculture with Osteoclasts
    Leukemia (2008) 22, 406–413 & 2008 Nature Publishing Group All rights reserved 0887-6924/08 $30.00 www.nature.com/leu ORIGINAL ARTICLE Atacicept (TACI-Ig) inhibits growth of TACIhigh primary myeloma cells in SCID-hu mice and in coculture with osteoclasts S Yaccoby1, A Pennisi1,XLi1, SR Dillon2, F Zhan1, B Barlogie1 and JD Shaughnessy Jr1 1Myeloma Institute for Research and Therapy, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA and 2ZymoGenetics Inc., Seattle, WA, USA APRIL (a proliferation-inducing Ligand) and BLyS/BAFF activity in patients with myeloma results in partial or no (B-lymphocyte stimulator/B-cell-activating factor of the TNF response,9,10 suggesting that additional growth factors and/or (tumor necrosis factor) family have been shown to be the cell-to-cell interactions may be involved in the growth and survival factors for certain myeloma cells in vitro. BAFF binds to the TNF-related receptors such as B-cell maturation antigen survival of myeloma cells within the BM. (BCMA), transmembrane activator and CAML interactor (TACI) Two TNF (tumor necrosis factor) family members known to and BAFFR, whereas APRIL binds to TACI and BCMA and to play key roles in normal B-cell biology, BLyS/BAFF (B- heparan sulfate proteoglycans (HSPG) such as syndecan-1. lymphocyte stimulator/B cell activating factor of the TNF family) TACI gene expression in myeloma reportedly can distinguish and APRIL (A PRoliferation-Inducing Ligand), also promote tumors with a signature of microenvironment dependence high low the survival of various malignant B-cell types, including (TACI ) versus a plasmablastic signature (TACI ).
    [Show full text]
  • Datasheet: VPA00331KT Product Details
    Datasheet: VPA00331KT Description: PRPF19 ANTIBODY WITH CONTROL LYSATE Specificity: PRPF19 Format: Purified Product Type: PrecisionAb™ Polyclonal Isotype: Polyclonal IgG Quantity: 2 Westerns Product Details Applications This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols. Yes No Not Determined Suggested Dilution Western Blotting 1/1000 PrecisionAb antibodies have been extensively validated for the western blot application. The antibody has been validated at the suggested dilution. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Further optimization may be required dependant on sample type. Target Species Human Species Cross Reacts with: Mouse, Rat Reactivity N.B. Antibody reactivity and working conditions may vary between species. Product Form Purified IgG - liquid Preparation 20μl Rabbit polyclonal antibody purified by affinity chromatography Buffer Solution Phosphate buffered saline Preservative 0.09% Sodium Azide (NaN ) Stabilisers 3 Immunogen KLH-conjugated synthetic peptide corresponding to aa 4-33 of human PRPF19 External Database Links UniProt: Q9UMS4 Related reagents Entrez Gene: 27339 PRPF19 Related reagents Synonyms NMP200, PRP19, SNEV Page 1 of 3 Specificity Rabbit anti Human PRPF19 antibody recognizes PRPF19, also known as PRP19/PSO4 homolog, PRP19/PSO4 pre-mRNA processing factor 19 homolog, nuclear matrix protein 200, nuclear matrix protein NMP200 related to splicing factor PRP19, psoralen 4 and senescence evasion factor. The PRPF19 gene is the human homolog of yeast Pso4, a gene essential for cell survival and DNA repair (Beck et al.
    [Show full text]
  • Genotyping of Breech Flystrike Resource – Update
    Project No: ON-00515 Contract No: PO4500010753 AWI Project Manager: Bridget Peachey Contractor Name: CSIRO Agriculture and Food Prepared by: Dr Sonja Dominik Publication Date: July 2019 Genotyping of breech flystrike resource – update Published by Australian Wool Innovation Limited, Level 6, 68 Harrington Street, THE ROCKS, NSW, 2000 This publication should only be used as a general aid and is not a substitute for specific advice. To the extent permitted by law, we exclude all liability for loss or damage arising from the use of the information in this publication. AWI invests in research, development, innovation and marketing activities along the global supply chain for Australian wool. AWI is grateful for its funding, which is primarily provided by Australian woolgrowers through a wool levy and by the Australian Government which provides a matching contribution for eligible R&D activities © 2019 Australian Wool Innovation Ltd. All rights reserved. Contents Executive Summary .................................................................................................................... 3 1 Introduction/Hypothesis .................................................................................................... 5 2 Literature Review ............................................................................................................... 6 3 Project Objectives .............................................................................................................. 8 4 Success in Achieving Objectives ........................................................................................
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • ASTRO Bone Metastases Guideline-Full Version
    1 Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline Stephen T. Lutz, M.D.,* Lawrence B. Berk, M.D., Ph.D.,† Eric L. Chang, M.D.,‡ Edward Chow, M.B.B.S.,§ Carol A. Hahn, M.D.,║ Peter J. Hoskin, M.D.,¶ David D. Howell, M.D.,# Andre A. Konski, M.D.,** Lisa A. Kachnic, M.D.,†† Simon S. Lo, M.B. ChB,§§ Arjun Sahgal, M.D.,║║ Larry N. Silverman, M.D.,¶¶ Charles von Gunten, M.D., Ph.D., FACP,## Ehud Mendel, M.D., FACS,*** Andrew D. Vassil, M.D.,††† Deborah Watkins Bruner, R.N., Ph.D.,‡‡‡ and William F. Hartsell, M.D.§§§ * Department of Radiation Oncology, Blanchard Valley Regional Cancer Center, Findlay, Ohio; † Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida; ‡ Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; § Department of Radiation Oncology, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada; ║ Department of Radiation Oncology, Duke University, Durham, North Carolina; ¶ Mount Vernon Centre for Cancer Treatment, Middlesex, UK; # Department of Radiation Oncology, University of Michigan, Mt. Pleasant, Michigan; ** Department of Radiation Oncology, Wayne State University, Detroit, Michigan; †† Department of Radiation Oncology, Boston Medical Center, Boston, Massachusetts; §§ Department of Radiation Oncology, Ohio State University, Columbus, Ohio; ║║ Department of Radiation Oncology, Sunnybrook Odette Cancer Center and the Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; ¶¶ 21st Century Oncology, Sarasota, Florida; ## The Institute for Palliative Medicine, San Diego Hospice, San Diego, California; *** Neurological Surgery, Ohio State University, Columbus, Ohio; ††† Department of Radiation Oncology, The Cleveland Clinic 2 Foundation, Cleveland, Ohio; ‡‡‡ School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania; §§§ Department of Radiation Oncology, Good Samaritan Cancer Center, Downers Grove, Illinois Reprint requests to: Stephen Lutz, M.D., 15990 Medical Drive South, Findlay, OH 45840.
    [Show full text]
  • Molecular Signatures in IASLC/ATS/ERS Classified Growth Patterns of Lung Adenocarcinoma
    RESEARCH ARTICLE Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma 1 1 1,2 1¤a Heike ZabeckID *, Hendrik Dienemann , Hans Hoffmann , Joachim Pfannschmidt , Arne Warth2,3, Philipp A. Schnabel3¤b, Thomas Muley2,4, Michael Meister2,4, Holger SuÈ ltmann2,5, Holger FroÈ hlich6, Ruprecht Kuner2,5¤c, Felix Lasitschka3 1 Department of Thoracic Surgery, Thoraxklinik, University Hospital Heidelberg, Heidelberg, Germany, 2 Translational Lung Research Centre Heidelberg (TLRC-H), German Centre for Lung Research (DZL), a1111111111 Heidelberg, Germany, 3 Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany, a1111111111 4 Translational Research Unit (STF), Thoraxklinik, University of Heidelberg, Heidelberg, Germany, 5 Cancer a1111111111 Genome Research (B063), German Cancer Research Center (DKFZ) and German Cancer Consortium a1111111111 (DKTK), Heidelberg, Germany, 6 Institute for Computer Science, c/o Bonn-Aachen International Center for a1111111111 IT, Algorithmic Bioinformatics, University of Bonn, Bonn, Germany ¤a Current address: Department of Thoracic Surgery, Lung Clinic Heckeshorn at HELIOS Hospital Emil von Behring, Berlin, Germany ¤b Current address: Institute of Pathology, Saarland University, Homburg/Saar, Germany ¤c Current address: TRONÐTranslational Oncology at the University Medical Center of Johannes OPEN ACCESS Gutenberg University, Mainz, Germany * [email protected] Citation: Zabeck H, Dienemann H, Hoffmann H, Pfannschmidt J, Warth A, Schnabel PA, et al. (2018) Molecular signatures in IASLC/ATS/ERS classified growth patterns of lung adenocarcinoma. Abstract PLoS ONE 13(10): e0206132. https://doi.org/ 10.1371/journal.pone.0206132 Editor: Stefania Crispi, Institute for Bioscience and Background Biotechnology Research, ITALY The current classification of human lung adenocarcinoma defines five different histological Received: April 4, 2018 growth patterns within the group of conventional invasive adenocarcinomas.
    [Show full text]
  • Transcriptome Sequencing and Genome-Wide Association Analyses Reveal Lysosomal Function and Actin Cytoskeleton Remodeling in Schizophrenia and Bipolar Disorder
    Molecular Psychiatry (2015) 20, 563–572 © 2015 Macmillan Publishers Limited All rights reserved 1359-4184/15 www.nature.com/mp ORIGINAL ARTICLE Transcriptome sequencing and genome-wide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder Z Zhao1,6,JXu2,6, J Chen3,6, S Kim4, M Reimers3, S-A Bacanu3,HYu1, C Liu5, J Sun1, Q Wang1, P Jia1,FXu2, Y Zhang2, KS Kendler3, Z Peng2 and X Chen3 Schizophrenia (SCZ) and bipolar disorder (BPD) are severe mental disorders with high heritability. Clinicians have long noticed the similarities of clinic symptoms between these disorders. In recent years, accumulating evidence indicates some shared genetic liabilities. However, what is shared remains elusive. In this study, we conducted whole transcriptome analysis of post-mortem brain tissues (cingulate cortex) from SCZ, BPD and control subjects, and identified differentially expressed genes in these disorders. We found 105 and 153 genes differentially expressed in SCZ and BPD, respectively. By comparing the t-test scores, we found that many of the genes differentially expressed in SCZ and BPD are concordant in their expression level (q ⩽ 0.01, 53 genes; q ⩽ 0.05, 213 genes; q ⩽ 0.1, 885 genes). Using genome-wide association data from the Psychiatric Genomics Consortium, we found that these differentially and concordantly expressed genes were enriched in association signals for both SCZ (Po10 − 7) and BPD (P = 0.029). To our knowledge, this is the first time that a substantially large number of genes show concordant expression and association for both SCZ and BPD. Pathway analyses of these genes indicated that they are involved in the lysosome, Fc gamma receptor-mediated phagocytosis, regulation of actin cytoskeleton pathways, along with several cancer pathways.
    [Show full text]
  • Genes with 5' Terminal Oligopyrimidine Tracts Preferentially Escape Global Suppression of Translation by the SARS-Cov-2 NSP1 Protein
    Downloaded from rnajournal.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Genes with 5′ terminal oligopyrimidine tracts preferentially escape global suppression of translation by the SARS-CoV-2 Nsp1 protein Shilpa Raoa, Ian Hoskinsa, Tori Tonna, P. Daniela Garciaa, Hakan Ozadama, Elif Sarinay Cenika, Can Cenika,1 a Department of Molecular Biosciences, University of Texas at Austin, Austin, TX 78712, USA 1Corresponding author: [email protected] Key words: SARS-CoV-2, Nsp1, MeTAFlow, translation, ribosome profiling, RNA-Seq, 5′ TOP, Ribo-Seq, gene expression 1 Downloaded from rnajournal.cshlp.org on September 28, 2021 - Published by Cold Spring Harbor Laboratory Press Abstract Viruses rely on the host translation machinery to synthesize their own proteins. Consequently, they have evolved varied mechanisms to co-opt host translation for their survival. SARS-CoV-2 relies on a non-structural protein, Nsp1, for shutting down host translation. However, it is currently unknown how viral proteins and host factors critical for viral replication can escape a global shutdown of host translation. Here, using a novel FACS-based assay called MeTAFlow, we report a dose-dependent reduction in both nascent protein synthesis and mRNA abundance in cells expressing Nsp1. We perform RNA-Seq and matched ribosome profiling experiments to identify gene-specific changes both at the mRNA expression and translation level. We discover that a functionally-coherent subset of human genes are preferentially translated in the context of Nsp1 expression. These genes include the translation machinery components, RNA binding proteins, and others important for viral pathogenicity. Importantly, we uncovered a remarkable enrichment of 5′ terminal oligo-pyrimidine (TOP) tracts among preferentially translated genes.
    [Show full text]